1219683-29-0

Upstream product

• 1078791-16-8 (S)-N-(4-bromophenyl)pyrrolidine-2-carboxamide 
• 1219632-33-3 C₂₄H₂₈BrN₃O₄ 

Downstream Products

• 1219632-39-9 diisopropyl (1,2-ethynediylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))biscarbamate 
• 1219632-38-8 dipropyl (1,2-ethynediylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))biscarbamate 
• 1219632-36-6 diethyl (1,2-ethynediylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))biscarbamate 
• 1219632-37-7 dimethyl ((1R,1′R) -((2S,2′S)-2,2'-(((ethyne-1,2-diylbis(4,1-phenylene)) bis(azanediyl))bis(carbonyl)) bis(pyrrolidine-2,1-diyl)) bis(2-oxo-1-phenylethane-2,1-diyl)) dicarbamate 
• 1219632-35-5 C₂₂H₂₄BrN₃O₄ 

Relevant academic research and scientific papers

HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene 2a. Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virology profile, along with some insights into the pharmacophoric elements associated with the GT-1a potency, are described.